alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
Searched for **https://www.imls.gov/**

 

19961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024

*Note:* This calendar view maps the number of captures of **https://www.imls.gov/**, *not* how many times the site was actually updated.

Look Up URL in general Internet Archive web collection.
# C_2014282EN.01003902.xml

| 25.8.2014 | EN | Official Journal of the European Union | C 282/39 |
| --- | --- | --- | --- |

25.8.2014

EN

Official Journal of the European Union

C 282/39

---

Action brought on 10 June 2014 — Coca-Cola v OHIM (Shape of a bottle)

(Case T-411/14)

2014/C 282/52

Language of the case: English

Parties

Parties

Applicant: The Coca-Cola Company (Atlanta, United States) (represented by: D. Stone and A. Dykes, Solicitors, and S. Malynicz, Barrister)

Applicant:

Defendant: Office for Harmonisation in the Internal Market (Trade Marks and Designs)

Defendant:

Form of order sought

Form of order sought

The applicant claims that the Court should:

| — | Annul the decision of the Second Board of Appeal of the Office for Harmonisation in the Internal Market (Trade Marks and Designs) of 27 March 2014 given in Case R 540/2013-2; |
| --- | --- |

—

Annul the decision of the Second Board of Appeal of the Office for Harmonisation in the Internal Market (Trade Marks and Designs) of 27 March 2014 given in Case R 540/2013-2;

| — | Order the defendant to pay the costs of proceedings. |
| --- | --- |

—

Order the defendant to pay the costs of proceedings.

Pleas in law and main arguments

Pleas in law and main arguments

Community trade mark concerned: Three-dimensional mark representing a shape of a bottle for goods in Classes 6, 21, 32 — Community trade mark application No 1 0 5 32  687

Community trade mark concerned:

Decision of the Examiner: Found the trade mark not eligible for registration in respect of a part of the goods applied for

Decision of the Examiner:

Decision of the Board of Appeal: Dismissed the appeal

Decision of the Board of Appeal:

Pleas in law: Infringement of Article 7(1)(b) CTMR .

Pleas in law:

---
# C_2016165EN.01002001.xml

| 10.5.2016 | EN | Official Journal of the European Union | C 165/20 |
| --- | --- | --- | --- |

10.5.2016

EN

Official Journal of the European Union

C 165/20

---

Order of the General Court of 21 March 2016 — Al Naggar v Council

(Case T-375/14) (1)

1

(2016/C 165/23)

Language of the case: French

The President of the Eighth Chamber has ordered that the case be removed from the register.

---

(1)  OJ C 245, 28.7.2014.

1

---
[Federal Register Volume 75, Number 45 (Tuesday, March 9, 2010)]
[Notices]
[Page 10755]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2010-4922]


-----------------------------------------------------------------------

COMMISSION ON CIVIL RIGHTS


Agenda and Notice of Public Meeting of the Mississippi Advisory 
Committee

    Notice is hereby given, pursuant to the provisions of the rules and 
regulations of the U.S. Commission on Civil Rights (Commission), and 
the Federal Advisory Committee Act (FACA), that a meeting of the 
Mississippi Advisory Committee to the Commission will convene on 
Thursday, March 25, 2010 at 2 p.m. and adjourn at approximately 4:30 
p.m. (CST) at Mississippi Center for Public Policy, 520 George Street, 
Jackson, MS. The purpose of the meeting is to plan a future civil 
rights project.
    Members of the public are entitled to submit written comments. The 
comments must be received in the regional office by April 25, 2010. The 
address is U.S. Commission on Civil Rights, 400 State Avenue, Suite 
908, Kansas City, Kansas 66101. Persons wishing to e-mail their 
comments, or to present their comments verbally at the meeting, or who 
desire additional information should contact Farella E. Robinson, 
Regional Director, Central Regional Office, at (913) 551-1400, (or for 
hearing impaired TDD 913-551-1414), or by e-mail to 
<a href="/cdn-cgi/l/email-protection#0f697d606d66617c60614f7a7c6c6c7d21686079"><span class="__cf_email__" data-cfemail="6e081c010c07001d01002e1b1d0d0d1c40090118">[email protected]</span></a>.
    Hearing-impaired persons who will attend the meeting and require 
the services of a sign language interpreter should contact the Regional 
Office at least ten (10) working days before the scheduled date of the 
meeting.
    Records generated from this meeting may be inspected and reproduced 
at the Central Regional Office, as they become available, both before 
and after the meeting. Persons interested in the work of this advisory 
committee are advised to go to the Commission's Web site, http://www.usccr.gov, or to contact the Central Regional Office at the above 
e-mail or street address.
    The meeting will be conducted pursuant to the provisions of the 
rules and regulations of the Commission and FACA.

    Dated in Washington, DC on March 4, 2010.
Peter Minarik,
Acting Chief, Regional Programs Coordination Unit.
[FR Doc. 2010-4922 Filed 3-8-10; 8:45 am]
BILLING CODE 6335-01-P


</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>
TS-P999BH



## Chemical structure diagram Attachment 2

Page 1/1

CBI
#### Broadway Electric Co., Inc., an Illinois Corporation, Plaintiff-Appellee, v. William Zeigler & Son, Inc., an Illinois Corporation, Defendant-Appellant.

Gen. No. 68-159. (Abstract of Decision.)

Second District.

April 17, 1969.

Runyard, Behanna, Conzelman & Schultz, of Waukegan, for appellant; Reno, Zahm, Polgate & Skolrood, of Rockford, for appellee.

Opinion by

JUSTICE ABRAHAMSON.

Not to be published in full.
<PAGE>   1
                                  EXHIBIT 24.1

                                POWER OF ATTORNEY

         The undersigned Director and Officer of The Ackerley Group, Inc.
("Company") appoints each of Denis M. Curley and Keith W. Ritzmann his true and
lawful attorney and agent, in name and on behalf of the undersigned, in any and
all registration statements (including without limitation, any registration
statement filed pursuant to Rule 462(b) promulgated under the Securities Act of
1933) and any and all amendments and post-effective amendments and exhibits
thereto in connection with the offering by the Company of shares of its common
stock under the Company's Employee Stock Purchase Plan and the Company's
Employees Stock Option Plan, and to do any and all acts and things and execute
any and all instruments which the attorney and agent may deem necessary or
advisable in connection therewith, without the other and with full power of
substitution and revocation, and hereby ratifying all that any such attorney or
his substitute may do by virtue hereby.

         Pursuant to the requirements of the Securities and Exchange Act of
1933, this Power of Attorney has been signed by the following person in the
capacity indicated on this 19th day of November, 1999.

                                  /s/ Barry A. Ackerley
                                  -----------------------------------------
                                  Barry A. Ackerley, Chairman of the Board,
                                  Chief Executive Officer and Director
| (logo) WELLS FARGO | **Corporate Trust Services**

  MAC R1204-010  9062 Old Annapolis Road  Columbia, MD 21045  Tel: 410 884 2000  Fax: 410 715 2380 |
|--------------------|----------------------------------------------------------------------------------------------------------------------------------|

 

 Re: Annual Statement ofCompliance for Credit Suisse First Boston Mortgage Securities Corp., CommercialMortgage Pass-Through Certificates, Series 2015-C3

 

 

Per the Pooling and ServicingAgreement dated as of August 1, 2015 (the "Agreement"), theundersigned, a duly authorized officer of Wells Fargo Bank, N.A., asCertificate Administrator ("Wells Fargo"), hereby certifies asfollows as of and for the year ending December 31, 2016 (the "ReportingPeriod"):

 

(a) A review of Wells Fargo'sactivities during the Reporting Period and of its performance under theAgreement has been made under such officer's supervision; and

 

(b) To the best of suchofficer's knowledge, based on such review, Wells Fargo has fulfilled all of itsobligations under the Agreement in all material respects throughout theReporting Period.

 

 

February 27, 2017

 

/s/ Brian Smith

BRIAN SMITH

Vice President

 

| Wells Fargo Bank, N.A. | (logo) Together we’ll  go far |
|------------------------|-------------------------------------|
#### § 349.20 Eyewashes.

The active ingredient of the product is purified water. The product also contains suitable tonicity agents to establish isotonicity with tears, suitable agents for establishing pH and buffering to achieve the same pH as tears, and a suitable preservative agent.

[68 FR 7921, Feb. 19, 2003]
Nemo

Piedmont

Meade

Pennington

Lawrence

Pennington

Meade

Lawrence

Dalton Lake TH Dalton Lake CG

Steamboat Rock PG

Boxelder Forks CG Boxelder TH

Pilot Knob TH

T03NR05E

T03NR06E

T02NR06E T02NR05E

T03NR07E

T04NR05E

T02NR07E

T03NR04E

T04NR06E

T02NR04E

T04NR04E

1

7

6

2

8

4

8

8

3

1

2

9

4

5 4

5

3

5

7

7

2 1

3

9

8

9

6

5

4

9

7

6

8

6

6

7

7

5

8

1

1

11

12

11

11

11

18

31

19

30

31

36

34 32

24

33

25

12

16

26

12

10

36

13

34

14

23

33

32

21

35

17

28

27

12

14

23 24

13

10

22

27 25

31

16

22

15

19

20

29

32 33

10

26

10

21

35

30

15

36

35

29

31

18

30 28

19

18

34

20

17

17

20

31 32 33

29

32

12

36

25

24

13

12

36

13 18 15 14 17

13 18 17 16 14

15 13 18 17 16

25 30 29 28 27 26 25

9

0 0.5 1 2 3

Miles

Steamboat Project Area

Recreation Sites

Recreation Sites

Centennial Trail

Steamboat Boundary

Private Land

/
§ 524.955 Florfenicol, terbinafine, and betamethasone acetate otic gel. ( a ) *Specifications.* Each milliliter of gel contains 10 milligrams (mg) florfenicol, 10 mg terbinafine, and 1 mg betamethasone acetate.
( b ) *Sponsor.* See No. 043264 in § 510.600(c) of this chapter.
( c ) *Conditions of use in dogs* — ( 1 ) *Amount.* Administer one dose (1 tube) per affected ear(s) and repeat administration in 7 days.
( 2 ) *Indications for use.* For the treatment of otitis externa in dogs associated with susceptible strains of bacteria (*Staphylococcus pseudintermedius*) and yeast (*Malassezia pachydermatis*).
( 3 ) *Limitations.* Federal law restricts this drug to use by or on the order of a licensed veterinarian.
[80 FR 13230, Mar. 13, 2015, as amended at 86 FR 14821, Mar. 19, 2021]
<TABLE> <S> <C>

<ARTICLE> 5
       
<S>                             <C>
<PERIOD-TYPE>                   3-MOS
<FISCAL-YEAR-END>                          DEC-31-1995
<PERIOD-START>                             JAN-01-1995
<PERIOD-END>                               MAR-31-1995
<CASH>                                       1,186,361
<SECURITIES>                                         0
<RECEIVABLES>                                1,258,699
<ALLOWANCES>                                         0
<INVENTORY>                                  1,020,744
<CURRENT-ASSETS>                             3,540,583
<PP&E>                                       5,822,451
<DEPRECIATION>                               3,105,033
<TOTAL-ASSETS>                               8,755,800
<CURRENT-LIABILITIES>                        3,843,883
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          7
<COMMON>                                           104
<OTHER-SE>                                  51,512,117
<TOTAL-LIABILITY-AND-EQUITY>                 8,755,800
<SALES>                                      1,074,643
<TOTAL-REVENUES>                             1,083,638
<CGS>                                          714,420
<TOTAL-COSTS>                                  714,420
<OTHER-EXPENSES>                             1,851,352
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                               4,390
<INCOME-PRETAX>                            (1,486,524)
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                        (1,486,524)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                               (1,486,524)
<EPS-PRIMARY>                                    (.14)
<EPS-DILUTED>                                    (.14)
        

</TABLE>
**IN THE SUPREME COURT OF PENNSYLVA NIA** 

IN RE: ORDER AMENDING RULE 227.1 OF THE PENNSYLVANIA RULES OF CIVIL PROCEDURE : : : : : : : NO. 627 CIVIL PROCEDURAL RULES DOCKET

**ORDER**
**PER CURIA M**  **AN D**  **NOW**, this 2nd day of July, 2015, upon the recommendation of the Civil Procedural Rules Committee ; the proposal having been published for public comment at 44 Pa. B

. 5563 (August 23, 2014): **IT IS**  **ORDERED** pursuant to Article V, Section 10 of the Constitution of Pennsylvania that Rule 227.1 of the Pennsylvania Rules of Civil Procedure is amended in the attached form. This **ORDER** shall be processed in accordance with Pa.R.J.A. No. 103(b), and shall be effective October 1, 2015

.
Additions to the rule are shown in bold and are underlined. Deletions from the rule are shown in bold and brackets.
Editorial Note on Part 878
Editorial Note: Nomenclature changes to part 878 appear at 73 FR 35341, June 23, 2008.

§ 878.4450 Nonabsorbable gauze for internal use. ( a ) *Identification.* Nonabsorbable gauze for internal use is a device made of an open mesh fabric intended to be used inside the body or a surgical incision or applied to internal organs or structures, to control bleeding, absorb fluid, or protect organs or structures from abrasion, drying, or contamination. The device is woven from material made of not less than 50 percent by mass cotton, cellulose, or a simple chemical derivative of cellulose, and contains x-ray detectable elements.
( b ) *Classification.* Class I (general controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter, subject to the limitations in § 878.9.
[53 FR 23872, June 24, 1988, as amended at 61 FR 1123, Jan. 16, 1996; 66 FR 38803, July 25, 2001]
-84 -82 -80 -78 -76 -74

 36

 38

 40

 42

▲ ★

▲

▲ ▲

★

▲

▲

▲

▲

 500

 1000

 1500

 100

18 12 06 00

06/29

NOAA HYSPLIT MODEL

 Backward trajectory ending at 2300 UTC 29 Jun 06

 EDAS Meteorological Data

Source

★ at 39.41 N 76.30 W Meters AGL
Editorial Note on Part 868
Editorial Note: Nomenclature changes to part 868 appear at 73 FR 35341, June 23, 2008.

§ 868.5105 External negative pressure airway aid. ( a ) *Identification.* An external negative pressure airway aid is a prescription device that applies negative pressure to a patient's neck to aid in providing a patent airway during procedures requiring anesthesia.
( b ) *Classification.* Class II (special controls). The special controls for this device are: ( 1 ) Clinical performance testing must document any adverse events observed during clinical use, including impaired blood flow, and demonstrate that the device performs as intended under anticipated conditions.
( 2 ) Non-clinical performance testing must demonstrate that the device performs as intended under anticipated patient positions, does not fail during use, and does not lose negative pressure capability. The following testing should be performed: ( i ) Ability of the device to maintain a seal during various patient positions;
( ii ) Device leakage testing to demonstrate the device maintains vacuum;
( iii ) Drop testing to ensure the device does not incur functional damage after dropping the device; and
( iv ) Functional testing after high and low storage temperature.
( 3 ) All patient contacting components must be demonstrated to be biocompatible.
( 4 ) Labeling must include: ( i ) A summary of clinical testing results, including any adverse events and evidence that effectiveness has been achieved.
( ii ) Technical specifications of the device, including collar sizes, maximum duration of use, operating temperature, and storage temperature range.
( iii ) Technical specifications of the vacuum source, including maximum vacuum level and operational vacuum level.
( iv ) Instructions for use that includes how to place the device, determination of size, verification of suction, reference to training materials, and information on troubleshooting the device if it does not attach properly.
( v ) A warning to screen patients for carotid artery disease due to the probable risk of the device to dislodge arterial plaques in the carotid artery.
( vi ) A warning to exclude patients with anatomical abnormalities.
( vii ) A warning not to use the device during medical procedures involving medications that contain propofol.
[82 FR 60867, Dec. 26, 2017]
§ 803.23 Where can I find information on how to prepare and submit an MDR in electronic format? ( a ) You may obtain information on how to prepare and submit reports in an electronic format that FDA can process, review, and archive at: *http://www.fda.gov/ForIndustry/FDAeSubmitter/ucm107903.htm*.
( b ) We may sometimes update information on how to prepare and submit reports electronically. If we do make modifications, we will ensure that we alert reporters by updating the eMDR Web page.
§ 876.5930 Rectal control system. ( a ) *Identification.* A rectal control system is a prescription device intended to treat fecal incontinence by controlling the size of the rectal lumen. The device is inserted in the vagina and includes a portion that expands to reduce the rectal lumen to prevent stool leakage and retracts to allow normal passage of stool. The device includes an external regulator to control the state of expansion.
( b ) *Classification.* Class II (special controls). The special controls for this device are: ( 1 ) Clinical testing must document the device acceptance data and the adverse event profile associated with clinical use, and demonstrate that the device performs as intended under anticipated conditions of use.
( 2 ) The elements of the device that contact vaginal tissue must be demonstrated to be biocompatible.
( 3 ) The cleaning and disinfection instructions for the device must be validated.
( 4 ) Non-clinical (bench) testing must demonstrate that the device performs as intended under anticipated conditions of use.
( 5 ) Non-clinical (bench) testing must demonstrate that the device does not: ( i ) Enhance the growth of *Staphylococcus aureus.*
( ii ) Increase production of Toxic Shock Syndrome Toxin-1 by *S. aureus.*
( iii ) Alter the growth of normal vaginal flora.
( 6 ) Labeling must include: ( i ) Specific instructions, contraindications, warnings, cautions, limitations, and the clinical training needed for the safe use of the device.
( ii ) The intended patient population and the intended use environment.
( iii ) Information on how the device is to be fitted, how the device operates, and recommendations on device maintenance.
( iv ) A detailed summary of the clinical testing pertinent to the use of the device, including a summary of the device- and procedure-related complications or adverse events related to use of the device, as well as relevant safety and performance information.
( 7 ) Patient labeling must be provided and must include: ( i ) Relevant contraindications, warnings, precautions, and adverse events/complications.
( ii ) Information on how the device operates and the recommended device maintenance (*i.e.*, care instructions), including cleaning and disinfection.
( iii ) Information on the patient population for which there was a favorable benefit/risk assessment.
( iv ) The potential risks and benefits associated with the use of the device.
[80 FR 30933, June 1, 2015]
<TABLE> <S> <C>

<ARTICLE> 5
<RESTATED> 
<MULTIPLIER> 1,000
       
<S>                             <C>
<PERIOD-TYPE>                   3-MOS
<FISCAL-YEAR-END>                          DEC-31-1996
<PERIOD-START>                             JAN-01-1996
<PERIOD-END>                               MAR-31-1996
<CASH>                                             985
<SECURITIES>                                         0
<RECEIVABLES>                                    3,351
<ALLOWANCES>                                        65
<INVENTORY>                                          0
<CURRENT-ASSETS>                                 5,419
<PP&E>                                           1,145
<DEPRECIATION>                                     340
<TOTAL-ASSETS>                                   6,315
<CURRENT-LIABILITIES>                            4,126
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                         1,490
<OTHER-SE>                                         577
<TOTAL-LIABILITY-AND-EQUITY>                     6,315
<SALES>                                          4,849
<TOTAL-REVENUES>                                 4,849
<CGS>                                                0
<TOTAL-COSTS>                                    2,939
<OTHER-EXPENSES>                                 1,615
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                                   8
<INCOME-PRETAX>                                    201
<INCOME-TAX>                                        20
<INCOME-CONTINUING>                                181
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                       181
<EPS-PRIMARY>                                     0.02
<EPS-DILUTED>                                     0.02
        

</TABLE>